TNFα blockade overcomes trastuzumab resistance in HER2+ breast cancer tumors not only by downregulating MUC4 expression, but also by transforming the TME to a less immunosuppressive state, characterized by increased NK cell activation and degranulation, a higher M1/M2 ratio, and decreased MDSC infiltration [71]. Here, MUC4 is linked to breast carcinoma.